Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients.
OBJECTIVE
Prospective pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 allele can significantly reduce the number of cases of abacavir-related hypersensitivity among HIV-infected patients treated with this drug. The aim of this study was to establish the frequency of the HLA B*5701 variant in HIV-infected Poles.


METHODS
The sequence-specific primer (SSP) test was used to assess the feasibility of the introduction of such testing in clinical practice. For this purpose, 234 randomly selected HIV-positive patients were screened using a low-resolution SSP assay, with HLA B*5701-positive results confirmed using a high-resolution test.


CONCLUSIONS
The HLA B*5701 variant was found in 11 of 234 subjects (4.7%). Testing with the selected method proved quick and reliable.
Parczewski
M
M
Department of Infectious Diseases and Hepatology, Pomeranian Medical University, Szczecin, Poland. mparczewski@yahoo.co.uk
Leszczyszyn-Pynka
M
M
Wnuk
A
A
Urbañska
A
A
Fuksiñska
K
K
Bander
D
D
Boroñ-Kaczmarska
A
A
D000328:Adult; D000483:Alleles; D015224:Dideoxynucleosides / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000235:genetics*; D005240:Feasibility Studies; D005260:Female; D005787:Gene Frequency; D005820:Genetic Testing; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D015235:HLA-B Antigens / Q000032:analysis / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011044:Poland; D016133:Polymerase Chain Reaction / Q000379:methods; D011237:Predictive Value of Tests; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D012882:Skin Tests; D000099227:Abacavir
D015224:Dideoxynucleosides; D015235:HLA-B Antigens; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C484830:HLA-B*57:01 antigen